Life SciencesLiability
Get a quote

TL;DR

Westchester County biotechs span the full lifecycle, from clinical-stage developers to commercial operators with marketed biologics. Coverage centers on a scaling D&O program, clinical trial liability, commercial products liability where products are on the market, and cyber sized to clinical PHI and drug master file data, all placed with A-rated specialty markets and shaped by the New York SHIELD Act.

Westchester County biotech

Biotech Insurance for Westchester County and the Lower Hudson Valley

Westchester County and the lower Hudson Valley north of New York City host a notable biotech presence that differs in character from the academic and startup ecosystem of Manhattan. Anchored by Regeneron Pharmaceuticals, which is headquartered in Tarrytown, the county combines large commercial-stage biologics operations with associated research activity and a growing base of bioscience real-estate development. The result is an insurance profile weighted toward companies that already have products, revenue, and complex regulatory exposure, alongside earlier-stage developers.

For a management team, this mix means the insurance program has to speak to more than a single stage of maturity. A clinical-stage company placing its first directors and officers tower and a commercial operator managing products liability across marketed biologics both operate in this cluster, and each requires a different structural approach. The pages that follow outline how the biotech coverage stack is built and repriced as a company moves from clinical development toward commercial and public-company status.

Get a quoteRun the Free Analyzer

Last updated 2026-07-13

Cluster shape

The Westchester biotech cluster

The defining feature of the Westchester and lower Hudson Valley cluster is the presence of large, commercial-stage biologics activity in a suburban New York setting. Regeneron Pharmaceuticals is headquartered in Tarrytown, and the surrounding county supports associated biotech and research operations along with dedicated bioscience real-estate development that has expanded available lab and manufacturing space.

This distinguishes the county from the New York City biotech page, where the cluster is organized around academic medical centers, incubators, and early-stage translational research. Westchester's profile skews toward companies with marketed products, active clinical programs, and larger headcounts, which changes both the size and the composition of the insurance program they require.

Because the cluster contains companies at very different stages, a broker working in this market has to underwrite the specific maturity of each risk rather than apply a single template. A commercial operator with biologics on the market, a clinical-stage developer approaching a public offering, and a research-focused venture all sit within the same county but carry materially different exposures.

Coverage architecture

Coverage the Westchester biotech stack requires

Directors and officers liability becomes effectively mandatory once a company takes on capital from outside investors, and it is the coverage that moves the most as a company grows. Clinical-stage companies raising Series A through C rounds typically carry limits in the range of $1M to $15M, with the program stepping up sharply as the company approaches an initial public offering or commercial launch, at which point larger Side-A difference-in-conditions towers protect individual directors and officers where the company cannot indemnify them.

Clinical trial liability is written per active trial and responds to bodily injury claims arising from human subjects in a company's studies. Commercial products liability activates for companies with marketed biologics and is sized to the product class and the company's revenue, covering claims tied to a product once it reaches patients. Both coverages sit alongside D&O rather than replacing it, and the products tower in particular grows as a portfolio of approved products expands.

Cyber coverage is sized to the sensitivity of the data a biotech holds, principally clinical protected health information and drug master file data that would be costly to expose or lose. For larger commercial-stage operators, the program may also extend to transactional and securities-oriented D&O that responds to the exposures created by public markets, financings, and mergers and acquisitions activity. Each layer is placed with A-rated specialty markets that understand life-sciences risk.

Regulatory + market context

New York regulatory considerations

Companies operating in Westchester County are subject to New York state data-security law in addition to federal requirements. The New York SHIELD Act adds a state data-security layer that imposes safeguards on private information belonging to New York residents and expands breach-notification obligations, which underwriters weigh when scoping a cyber program for a biotech holding clinical and employee data.

For commercial and clinical-stage biotechs alike, the regulatory picture combines FDA oversight of products and trials with state privacy obligations. A well-structured program aligns the cyber and management liability coverages to these overlapping regimes so that a regulatory inquiry or data event does not fall between policies.

Frequently asked

Common questions from Westchester County biotech operators

What makes Westchester biotech distinct from the New York City cluster?

Westchester County and the lower Hudson Valley host a suburban biotech presence weighted toward commercial and clinical-stage companies, anchored by Regeneron Pharmaceuticals in Tarrytown and supported by associated research operations and bioscience real-estate development. This differs from the New York City page, where the cluster is organized around academic medical centers and early-stage translational research. The practical effect is that Westchester programs more often address marketed products and public-company exposures rather than pre-clinical startup risk.

How does D&O scale from clinical-stage to commercial or IPO-stage biotech?

Directors and officers liability becomes effectively mandatory once outside investor capital arrives, and it grows with the company. Clinical-stage companies raising Series A through C rounds typically carry limits in the range of $1M to $15M, and the program steps up sharply as the company approaches an initial public offering or commercial launch. At that stage, larger Side-A difference-in-conditions towers are added to protect individual directors and officers directly.

When does commercial products liability activate for a biotech?

Commercial products liability activates once a company has marketed biologics, meaning products that have reached patients. The limit is sized to the product class and the company's revenue, and it typically expands as a portfolio of approved products grows. It sits alongside, rather than replacing, the clinical trial liability that responds to injuries arising from human subjects in active studies.

How do cyber coverage and the New York SHIELD Act affect a Westchester biotech?

Cyber coverage is sized to the clinical protected health information and drug master file data a biotech holds, both of which are costly to expose or lose. The New York SHIELD Act adds a state data-security layer that imposes safeguards on the private information of New York residents and expands breach-notification duties. Underwriters weigh these state obligations, alongside federal requirements, when scoping the cyber program.

Biotech insurance practice →Biotech IPO insurance checklist →NYC biotech insurance →New York state guide →

Free coverage review

A specialist will reach out by end of business day.

Programs placed through A-rated specialty markets. Send your contract, insurance schedule, or current COI - a specialist returns a clause-by-clause read by end of business day.

Get my quote

Specifically for Westchester County biotech operators.

Programs placed through A-rated specialty markets. Your specialist handles unlimited certificates of insurance, annual coverage reviews, and claims advocacy.